It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: rounda
a reply to: HawkEyi
Conclusions: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
pubmed.ncbi.nlm.nih.gov...
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
Chien-Te Tseng et al. PLoS One. 2012.
originally posted by: MichiganSwampBuck
"The Benefits outweighs the Risk"
That is not an absolute statement for individuals or small sub-groups of the population obviously. The probabilities favor a beneficial out come (of some unstated value) based on the recorded effects and general health data of the entire population.
However, on an individual basis, it a crap shoot where you roll the dice for a range of results from fully beneficial to severe adverse reactions and if you get snake eyes, death. Once committed to taking the jab you just have to hope you have benefited and not ended up at a health disadvantage instead.
The question you have to ask yourself before getting the jab is, "Do you feel lucky? Punk!"
originally posted by: AaarghZombies
originally posted by: rounda
a reply to: HawkEyi
Conclusions: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
pubmed.ncbi.nlm.nih.gov...
Your quoting a research paper from 2012
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
Chien-Te Tseng et al. PLoS One. 2012.
Way to go quoting out of date data.